Oligomerix is a biotechnology company targeting tau protein with small molecule inhibitors for neurodegeneration. Our platform includes a lead compound entering Phase 1 human testing, 2nd generation compound series and a companion biomarker program. We completed our pre-clinical program in 2021 and are transitioning into Ph 1 in 2022. We are seeking near term investment/collaboration to help accelerate these programs through clinical development.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
OLX-07010
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
